WINNER
Baxter BioPharma Solutions
Phase IV Vial and Syringe Filling Facility

FINALISTS
AstraZeneca Daiichi Asubio Pharma
Janssen Pharmaceutica Wyeth Pharmaceuticals

Special Recognition
Biolex Therapeutics
From Concept to Completion

Unit Operations and Process Integration from One Source

GEA Liquid Processing is your one source for Pharmaceutical and Bioprocess Systems. Whether it is delivering a single GEA Unit of Operation, or a complete cGMP Process Line, GEA Liquid Processing can provide you security of outcome to meet your business objectives.

Our in-house services include:
- Basic Engineering
- P&ID Development
- Detail Engineering
- Procurement
- Fabrication
- Automation (GAMP)
- Testing and Qualification
- After Sales Service

Leading Technologies. Individual Solutions.

GEA is pleased to be identified by Wyeth BioPharma Grange Castle as a Primary Project Partner!

GEA Liquid Processing

Niro Inc.
9165 Rumsey Road • Columbia, MD 21045 • USA
Tel: 410-997-7010 • Fax: 410-997-5021
E-mail: info@niroinc.com • Web: www.nirolnc.com

GEA Process Technologies Ireland Ltd.
Ash House, Lime Tree Avenue • Millenium Park, Naas • Co. Kildare • Ireland
Tel: 353-0-45981200 • Fax: 353-0-45981232
E-mail: postbox@geapt.ie • Web: www.geapt.ie
Bovis Lend Lease is proud to have worked in joint venture with Jacobs Engineering to deliver Wyeth’s world-class biopharmaceutical campus at Grange Castle, Dublin.

Bovis Lend Lease’s role on the Wyeth project gives strength to our long standing presence in Ireland and provides us with a platform for our global service delivery in Ireland’s future development as a centre of excellence.

Our services:
- Master planning
- Commercial
- Project management
- Procurement
- Start-up
- Consultancy
- Design
- Engineering
- Construction
- Quality assurance & compliance
- Integrated commissioning & validation

Contact: Sue Shufflebotham-Devereaux
Telephone: +44 (0) 161 254 1700
Facsimile: +44 (0) 161 254 1701
Email: sue.shufflebotham-devereaux@eu.bovislendlease.com
Facility of the Year Special Edition

PHARMACEUTICAL ENGINEERING
A Supplement to MARCH/APRIL 2006

Articles

Winner:
6 Baxter BioPharma Solutions
Phase IV Vial and Syringe Filling Facility

Finalist:
12 AstraZeneca
Large-Scale Laboratory (LSL) Facility

Special Recognition:
16 Biolex Therapeutics
Phase II GMP Facility Expansion

Finalist:
18 Daiichi Asubio Pharma Co., Ltd.
New Bio Plant (NBP)

Finalist:
22 Janssen Pharmaceutica
Small Volume Area (SVA) – Powder Unit

Finalist:
26 Wyeth Pharmaceuticals
Wyeth BioPharma Campus at Grange Castle

30 An Interview with Peter Bigelow
Facility of the Year Judging Panel Chair
ISPE would like to thank the following Facility of the Year Finalists’ key project participants for their generous advertising support which made this Special Edition possible.

Advertiser’s Index

APPLIED CONTAINMENT ENGINEERING ...................... 5
BNS ENGINEERING ................................................. 25
BOULTING GROUP ................................................. 11
BOVIS LEND LEASE ................................................ 3
EISAI MACHINERY .................................................. 29
EMERSON PROCESS MANAGEMENT ....................... 32
FOSTER WHEELER .................................................. 25
GEA LIQUID PROCESSING ......................................... 2
JACOBS ENGINEERING GROUP ............................... 15
JANSSEN PHARMACEUTICA ................................... 23
JGC CORP. ............................................................ 19
O’NEAL, INC. ......................................................... 17
PHARMADULE ......................................................... 7
SKAN AG .............................................................. 24
STERIS .............................................................. 27
THERMAL TRANSFER ............................................. 13
US FILTER ............................................................ 9
YOKOGAWA ......................................................... 21
Baxter BioPharma Solutions

A New Shot at Contract Services

A state-of-the-art response to an under-served market... groundbreaking use of modular design... effective use of the latest and most advanced high-speed syringe filling technology. Any one of these attributes is noteworthy, but taken in combination, they spell one thing: pharmaceutical manufacturing excellence. As the winner of the 2006 Facility of the Year Award, Baxter Pharmaceutical Solutions (BPS) has demonstrated world-class quality with its Phase IV Vial and Syringe Filling Project in Bloomington, Indiana, US. Commissioned in mid-2005, the Phase IV facility is the company’s response to a market opportunity to provide large-scale syringe filling, aseptic formulation, vial filling, lyophilization, terminal sterilization, and flexible formulation capacity for a variety of challenging products such as insoluble solutions and vaccines.

“With its new Phase IV operation, Baxter, in conjunction with design/build partner Pharmadule AB, has demonstrated true leadership in the rapidly growing contract manufacturing sector,” said Peter Bigelow, Senior Vice President of Consumer Healthcare Manufacturing for Wyeth and Chairman of the 2006 Facility of the Year Award Judging Panel. “It is rare to find such an impressive array of cutting-edge filling technologies all within one facility. We were also very impressed with Baxter’s use of bolt-on removable components, 3-D design throughout, and the combination of innovative technology and practical functionality – a difficult balance for an aseptic environment. These are among the many qualities that make this a truly world-class facility.”

The Phase IV Project consisted of partial demolition and renovation of an existing building as well as new construction, and was completed in only 22 months from start of detailed design to US FDA approval. The project combines conventional construction for administrative areas with state-of-the-art modular construction for manufacturing areas. Additionally, another off-site building was renovated for expansion of packaging operations.

Continued on page 8.
How fast can you get there?

Pharmadule offers the fastest and most profitable way to implement complete pharmaceutical or biotech facility projects. We can save 6 - 12 months on most projects compared to conventional construction.

Our areas of expertise:

- Biopharmaceuticals
- Chemical API
- Fill & Finish with Aseptic Processing
- Oral Solid Dosage

Our value adding services include:

- Process Design and Engineering
- Facility Design and Engineering
- Project Management
- Commissioning and Qualification (IQ and OQ)
- Centralized Documentation (from initial design to handover for the complete scope)

Our facilities comply with cGMP requirements and can be designed to meet Biological Safety Levels (BSL) and High Potency Containment.

Pharmadule guarantees an on-time, predictable project delivery that meets the highest quality standards.

Congratulations Baxter Healthcare Corporation for reaching the final of the Facility of the Year Award

www.pharmadule.com
and Baxter added large-scale cold storage capacity for temperature sensitive products.

**Filling a Need**

As pharmaceutical companies become increasingly focused on the R&D pipeline and its impact on sales and marketing, contract manufacturing is becoming a cost-effective alternative to large capital projects—especially if production volumes don’t warrant the investment. BPS, a full-service contract manufacturing organization serving the pharmaceutical and biopharmaceutical industries, recognized a need to provide these services all “under one roof,” a need that had previously been unmet by other contract manufacturers.

The Bloomington facility is a full-service contract manufacturing plant providing form, fill, and finish services to the pharmaceutical industry for a variety of sterile product dosage forms. These products include solutions, suspensions, and freeze-dried powders encompassing human and veterinary small molecule, biologic, biotech, vaccine, and protein pharmaceuticals. BPS wanted to ensure its facility’s capabilities could meet client production needs with the growing market preference for prefilled syringes.

For consumers, pre-filled syringes have advantages over traditional packaging in vials, including reduced microbial contamination risk due to less manipulation and exact dosing for greater patient safety and compliance. From a manufacturing perspective, pre-filled syringes improve a client’s bottom line as less overfill is required than with vials. Plus, a variety of customized features can be used to meet end users’ needs, potentially resulting in product differentiation and market share expansion.

**Technologies Leading the Way**

The Baxter facility is the first to use a new high-speed syringe-filling system, which can fill 500 syringes per minute, and is a considerable improvement over the 300 syringes per minute capacity of existing technologies. One of the key attributes of the machine that has increased throughput is the tube handling system, which now handles tubes in parallel instead of serially. The increased throughput of the filler has saved considerable capital costs on the project by alleviating the need for two machines and additional clean space and gowning room.

Another focus of the facility was to provide a new formulation and filling service for manufacturers of insoluble and unstable drugs. The new technology revolves around Baxter’s Nanoedge process, which increases solubility and reduces excipient side effects in formulation. Drug particles are reduced to 100 nanometers in diameter, and then coated with a thin layer of proprietary excipient, creating drug particles that dissolve more rapidly when injected or infused.

Nanoedge has allowed Baxter to solve seemingly intractable formulation problems. This is based on the dilemma of current formulation situations that would ordinarily take one part drug to 10,000 parts of water to dissolve. Instead of requiring a patient to endure a 10 L infusion, Nanoedge would allow for formulations in 10 ml doses. The flexible formulation space included as part of this facility enabled Baxter to commercialize this technology.

**“Farming Out” Process Design**

The manufacturing portion of the facility expansion was a design/build project provided and qualified by Pharmadule AB, a provider of modular facilities for the pharmaceutical and biopharmaceutical industry. Baxter pursued modular technology because it provided the quickest return on investment with minimal risk and demand on internal resources.
When so much is riding on your process, you want peace of mind.

At USFilter, we offer our customers the largest global network of local service centers in the industry, so we can be at your plant in 24 hours when you need us. From custom service contracts and preventive maintenance agreements to validation assistance and a large inventory of spare parts and consumables, we will help you keep your production process operating smoothly.
The benefits included: shaving 12 months off the delivery schedule; reduced demand on client resources; integrated validation in the basic design phase; elimination of a large portion of installation, commissioning and qualification at the site; and a reduction in local resources and disruption at worksite and to the existing operation.

**Offsite Facility Testing and 3-D Design**
Modular technology and delivery used for design and construction involved the offsite fabrication of the entire manufacturing process facility, inclusive of structural steel, poured concrete floors, internal finishes, process and utility piping, electrical, automation, HVAC and process and utility equipment, and systems. The modular facility was fabricated in a factory in Sweden, pre-assembled, tested, pre-qualified, disassembled, packed, and shipped across the Atlantic Ocean, then reassembled, and commissioned and validated at the site.

Three-dimensional design was used throughout the facility, which facilitates any later remodelling or expansion of the facility. Airflow patterns in critical areas such as the filling suites were stimulated before finalizing the 3-D design. This allowed for the design to change before the start of construction to optimize airflow patterns.

Modularization in combination with the use of 3-D design assured a high level of accuracy in the placement and access to equipment and services. Time and efficiency gains of modularizing the manufacturing areas were realized in Phase II and III expansion projects, which drove the decision to again pursue modularization for the Phase IV project.

The Phase IV facility was designed with foresight to minimize any impact for expansion of the vial filling and lyophilization capacity related to the market demands. The facility modules are designed with 12' x 14' removable panels that are bolted with gaskets to allow for clean and quick access to the building. Equipment can be added or removed easily, as well as the quick addition or manufacturing modules for a fast response to market demand without disturbing the ongoing production.

The facility is designed to add a mirror manufacturing suite on the opposite side of the building, which will then utilize the personnel and material corridors as a central spine. Wide, open rooms allow for ample working space and flexibility within the facility.

**Tracking and Quality Control**
The facility uses a new ERP/MRP enterprise planning system from Oracle to facilitate the tracking and management of material throughout the manufacturing process, providing 100 percent accountability of product tracking from raw materials through packaging. The platform features a production-scheduling program that will monitor constraints and anticipate potential problems, which is a task that previously required six full-time managers.

**Environmental Considerations**
By constructing the modular manufacturing facility off-site in a dedicated manufacturing facility, Pharmadule was able to greatly reduce the project’s impact on the local environment.

Site work logistics were established to assure that no waste or debris entered a creek that runs through the campus. Silt fences and other erosion control measures were employed. Electric and gas utilities were tunnelled under the creek to not disturb fish and wildlife.

**Leading the Way in Parenteral Contract Services**
As the winner of the 2006 Facility of the Year Award, the Phase IV Project is the realization of BPS’s vision to provide contract manufacturing services for pre-filled syringes and lyophilized vials. Through a creative and innovative mix of conventional construction for support areas combined with state-of-the-art modular construction of the manufacturing areas, the project has propelled BPS to become the world’s largest supplier of pre-filled syringes - with a greatly expanded capacity for delivering the unit dosage forms that are critical for vaccines being re-developed without preservatives. As a result, Baxter is now the parenteral contract services leader of pre-filled syringes in North America with a total capability of filling up to 300 million 1- to 3-mL syringes each year including automated inspection, labelling, and packaging. For pharmaceutical companies choosing to outsource these operations, the BPS Phase IV Project provides a state-of-the-art, award-winning solution.
AstraZeneca
Delivering a Multi-Purpose API Plant

In response to an increased number of development projects, more complex manufacturing processes and due to increased drug substance potency, AstraZeneca is investing in upgrading, replacing, and building new key facilities. The Large Scale Laboratory (LSL) at Macclesfield, UK represents a significant element of this program. As a unique brown-field development, the project utilizes a holistic approach to the venture – from conceptual analysis through establishment of routine operation.

The LSL facility manufactures emerging compounds from AstraZeneca’s therapy areas, including gastrointestinal, cardiovascular, respiratory, oncology, and neuroscience. It consists of one large, three-story building comprising three processing areas containing 16 reactors and ancillary equipment. In addition, there are separate chromatography and hydrogenation suites. Significantly, it is an API manufacturing facility capable of a range of different operating scales with a scope of containment solutions capable of a wide variety of chemical and physical transformations and rapidly configurable to deliver any combination thereof.

Creativity, Ingenuity, and Teamwork

In conjunction with Jacobs Engineering, AstraZeneca made an extraordinary effort during the conceptual stage of the project to ensure the requirements of such an asset were relevant for future needs of the company. This resulted in key features, including:

- a diverse range and combination of processing equipment and technologies
- a modular layout concept
- an innovative combination of containment approaches that allows handling of substances with an OEL down to 30ngm⁻³

The modular layout concept was not only cost effective but allowed the facility to be doubled in scale on a reserved footprint using the existing design. The entire infrastructure delivered by the original project was sized for the larger plan.

State-of-the-art chromatography technologies were used to increase the flexibility of the facility. For rapid delivery of critical path clinical supplies, the LSL includes a large-scale chromatography facility for separation of intermediates and final APIs. When key steps are made with optimal chemistry and chromatography as a part of the process, strategic route selection decisions can be made. Thus, otherwise non-viable chemical routes can become a commercial reality faster and earlier than anticipated.

A significant component of the chromatography investment is the Simulated Moving Bed (SMB), an innovative continuous manufacturing technique which allows separation of bi-
nary mixtures with far lower use of stationary phases and solvents. Particularly for chiral chromatography, this reduces costs significantly and can make otherwise uneconomic separations viable.

The project was delivered via a novel concept developed within AstraZeneca known as “alliancing.” The keys to successful alliancing were in developing a single, integrated multi-disciplinary and multi-skilled project team from a small range of partner companies and AstraZeneca personnel. This was accomplished by forming mutually-beneficial relationships based on open, honest, and trusting relationships in which AstraZeneca's need to obtain value for money, superior safety, schedule, and regulatory compliance adherence was equal to the partners' need to make a fair return.

The Result
The Large Scale Laboratory has been a highly successful venture between AstraZeneca and its Alliance Partners to deliver a state-of-the-art facility. The

Concludes on page 14.
Facility of the Year Finalist

“The LSL project has demonstrated its ability to shorten production time through innovation, processing efficiencies, and well understood and dependable equipment.”

LSL project has demonstrated its ability to shorten production time through innovation, processing efficiencies, and well understood and dependable equipment. As a result, the facility has enabled Campaign 2 (C2) manufacture of drug substance for volunteer studies to be taken off the critical path. In addition to a significant business advantage, the facility provides an optimum range of manufacturing scales with rapidly configurable containment options to suit the compound being processed, without compromising operability. The LSL project is unique in that it represents a complete solution to AstraZeneca’s C2 manufacturing needs, delivering flexibility and adaptability, yet achieving these goals through a novel project approach in a highly cost effective manner.

Meet the 2006 Facility of the Year Award Judging Panel

Peter Bigelow, Judging Panel Chair
Senior VP Consumer Healthcare Manufacturing, Wyeth

Tony Felicia
VP R&D Administration, AstraZeneca

Christian Ilsoe
Vice President, Quality and Validation Assurance, NNE A/S

Brian H. Lange, PE
Director – Sterile and Packaging Operations Engineering, Merck & Co., Inc.

Ulrich Rudow
VP Worldwide Engineering and Real Estate, Johnson & Johnson

Raymond H. Scherzer
Senior Vice President of Engineering, Technology and Capital Management in Global Manufacturing and Supply, GlaxoSmithKline

Andrew A. Signore, PE, PMP, DBIA
President, IPS

Andy Skibo
VP Corp. Engineering and Capital Production, Amgen
Congratulations to AstraZeneca and to Wyeth

On Your Outstanding Achievements

www.jacobs.com
Biolex Therapeutics

Simplicity in Approach Leads to Facility Excellence

In an industry in which each new facility or facility renovation project is bigger, more elaborate, and more complex than the last, simplicity is sometimes the best strategy. In expanding the production capabilities of its Pittsboro, North Carolina, US, manufacturing facility, Biolex Therapeutics adopted the “simple and practical” approach for all aspects of the facility expansion and the operation of the completed facility. As recipient of the 2006 Facility of the Year Special Recognition, Biolex has demonstrated how “simple is better” can yield the following benefits:

1. additional manufacturing capacity, which conforms to U.S. and European GMPs

2. flexible manufacturing space, which can be used for production of research grade, pre-clinical and clinical phase materials

3. exceedingly quick and economical facility delivery

Biolex engaged O’Neal, Inc. to provide integrated design, engineering and construction services on a design/build basis for the facility expansion project. The expansion allowed Biolex to convert an additional 7,500 square feet of a 50-year-old, brick textile mill located in the historic district of Pittsboro into manufacturing space for the production of several complex recombinant proteins, including bulk material for Locteron™, the company’s novel, controlled release formulation of interferon. Locteron just completed Phase 1 clinical trials and this additional capacity has allowed Biolex Therapeutics to immediately ramp up material for Phase 2 clinical trials.

Process Innovation

The Biolex Phase II expansion showcases key innovative technologies in the company’s manufacturing process. Rather than using traditional cell culture methods, the Biolex process employs the small, free-floating aquatic plant, Lemna. Lemna is a clonal plant known to be genetically stable. The method involves introducing a specific gene sequence into the cells of the plant which serve as the template for constructing a target therapeutic protein. By using a whole, intact organism, the environmental requirements for clonal replication and therapeutic expression are minimized. The plant grows in a wide range of conditions in its natural environment, and requires a simple aqueous media of basal salts, a light source, and CO₂ to produce human therapeutics.

By using this expression system, the upstream production process equipment and utility systems required were minimized. The need for stainless steel tanks with CIP and SIP capabilities, WFI, and clean steam systems were eliminated – as were the capital expense and long lead times associated with such equipment.

Fast-Track Project Delivery

The strategy to use a transgenic plant to produce human therapeutics resulted in a facility project involving mostly architectural, HVAC, and electrical design and construction elements rather than the often complex equipment and...
utility requirements typically associated with biological manufacturing facilities. The project team was able to further capitalize on these advantages by using off-the-shelf, packaged utility systems to capture capital savings and shorten delivery times over custom designed utility equipment.

Additionally, Biolex used modular-constructed environmental chambers for bioproduction suites within the new expansion area. These suites were slightly customized versions of chambers that have traditionally been used in the agricultural industry and in academic institutions for plant growth and research applications. The suites provide Biolex optimal environment growth conditions in a controlled, contained environment. The modular design of the units allowed site construction to commence while the suites were being constructed in parallel. Once the suites arrived, they were simply erected in place and tied into the installed utility systems. Further time savings were captured by using an enhanced commissioning approach in the validation of the suites.

By emphasizing simplicity of design, construction, and operation, Biolex's expansion project was completed from the beginning of design through the completion of OQ validation in five months, from March to August 2005. The project was completed under budget with no safety incidents and with superior quality.

"The technology employed by Biolex Therapeutics is an excellent example of manufacturing innovation," said Peter Bigelow, Senior Vice President of Consumer Healthcare Manufacturing for Wyeth and Chairman of the 2006 Facility of the Year judging panel. "Instead of using traditional cell culture methods, the Biolex manufacturing process employs a unique expression system. We found that to be a very intriguing new innovation in biotechnology."
For patients suffering from cardiovascular disease, central nervous system, and immune systems disorders, effective treatments cannot come too soon. To shorten the product delivery cycle for new drugs in these therapeutic areas, Daiichi Asubio Pharma Co., Ltd. (ASB), a subsidiary of the Daiichi Pharmaceutical Group, constructed a new multi-product and multi-scale plant in Gunma Prefecture, Japan. As a multi-product and multi-scale “launch plant” for bulk biopharmaceutical products, the New Bio Plant (NBP) provides small-scale manufacturing for Phase 2 clinical trials as well as large-scale commercial manufacturing. Leading Japanese engineering and construction company JGC Corporation was selected to execute engineering, procurement, construction, and commissioning and qualification.

A unique combination of cutting-edge production processes makes the NBP unique among pharmaceutical facilities in Japan, and perhaps, the entire world. The $30 million plant is equipped with two fermenters (300 liter and 4,500 liter), separation, reaction, purification and lyophilization systems, and was completed in a remarkable 26 months from start of conceptual study to readiness for Performance Qualification (PQ).

**State-of-the-Art Peptide Production**

A unique feature of the NBP is a peptide production process by which peptides are produced on a commercial scale from recombinant microorganisms. In the NBP, enzymatic reactions apply a unique, self-developed process.

**PROJECT:** New Bio Plant (NBP)**

**LOCATION:** Gunma Prefecture, Japan

**DESIGN-BUILD PARTNER:** JGC Corporation

Exterior views.
Guaranteeing performance and ensuring trust

*JGC congratulates Daiichi Asubio Pharma Co., Ltd. on being selected as a finalist in this year's remarkable Facility of the Year Award competition*

Our global information network brings a comprehensive understanding of pharmaceutical industry trends, while our state-of-the-art technologies meet the ever growing needs of the client. In expanding from Japan outwards, JGC’s full-scope capabilities have assisted multinational pharmaceutical manufacturers to establish worldwide production bases.

*Ultra fast-track project execution under a full turnkey, lump-sum contract*

2-3-1 Minato Mirai, Nishi-ku, Yokohama 220-6001, Japan
Tel: 81-45-682-1111 Fax: 81-45-682-1112
www.jgc.co.jp
enzyme to achieve high productivity and high purity. The hybrid process for peptide production utilizes both bio and chemical synthesis. Lyophilization is applied for the bio production process.

**A Closed System to Prevent Cross-Contamination**

Flexible processing and prevention of cross-contamination are essential requirements for a multi-product and multi-scale plant such as the NBP. As a result, the plant features such innovations as closed disposable trays for lyophilization, a closed purification process, a closed continuous solid-liquid separation system, and a unique powder feed system.

"Flexible processing and prevention of cross-contamination are essential requirements for a multi-product and multi-scale plant such as the NBP."

For flexible processing, mobile equipment has been adapted to meet the requirements of different products and production scales. Common utility stations that can be conveniently connected to variously sized equipment are made available to each production room. Elongated body fermenters and other vessels enable wide-ranging volumes of culture and products to be manufactured. All of these contribute to cost reductions through the minimization of space, piping, cable, valves, and instruments.

Manufacturing Execution Systems (MES) and Digital Control Systems (DCS) offer easily configurable tools for operation and product changes, meeting the multi-product and multi-scaler requirements. The DCS was developed based on ISA S88 for changes of recipe and control operations. By communicating with the DCS, the MES controls the manufacturing step and adopts a bar-code system to prevent cross-connection of piping and erroneous feed of raw material.

**Reliability and Compliance**

For improved reliability, the NBP is equipped with uninterruptible co-generative electric power, e-mail warning transfer system to mobile phones, an automatic emergency stop system for earthquakes, Web cam monitoring, and IC card access control.

Plus, this world-class and critically important plant is distinguished by full cGMP compliance (Impact Assessment, Risk Assessment and Design Qualification (DQ)), ultra fast track project execution, and in its design phase, 3-D CAD engineering as well as Computational Fluid Dynamics (CFD). Significant contributions to the pharmaceutical manufacturing industry are highly anticipated to result in a stable supply of biobulk products while shortening the period required for new drug development.
"Is your plant lean, agile and flexible?"

Your Automation Solution Should Be.

This is the promise behind vigilantplant.

The clear path to operational excellence

Making critical plant information fully visible is just the beginning of the vigilant cycle. Seeing clearly gives you the knowledge necessary to anticipate the changes required in your process. Knowing in advance brings you the speed and flexibility to optimize your plant in real time. And by acting with agility, you are able to adapt to the ups and downs of your business environment. VigilantPlant excels at bringing out the best in your plant and your people - keeping them fully aware, well informed, and ready to face the next challenge.

SEE CLEARLY
Improve visibility of information?

InfraSpec NR800 FT-NIR Analyzers
- Continuous high speed on-line analysis
- Multiple channels, multiple properties/parameters
- Minimizing production cost based on PAT approach

KNOW IN ADVANCE
Secure predictability of process

CENTUM CS 3000: Production Control System
- Object oriented architecture based upon ISA-88 standards
- Advanced tools to help users comply with 21 CFR Part 11
- Batch performance monitoring through Batch Plant Information Management

ACT WITH AGILITY
Enable agility of business

Validation Services
- Shorter validation time and decreased time to market
- Modular batch approach
- Expertise to integrate various subsystems into one solution

InfraSpec NR800 FT-NIR Analyzers
Continuous high speed on-line analysis
Multiple channels, multiple properties/parameters
Minimizing production cost based on PAT approach

Find out more about Yokogawa and its process automation solutions at:
www.yokogawa.com/iab/industries/
In 2003, the Janssen Pharmaceutica chemical production site in Geel, Belgium installed a new powder-handling installation aptly named the Small Volume Area (SVA) – Powder Unit. This Small Volume Area (SVA), the first of its kind within Janssen’s parent company, Johnson & Johnson, is a unique combination of state-of-the-art micronizing equipment and high-tech separation of the working environment using isolators (glove boxes).

The installation is to be used to obtain the correct particle size distribution for the most potent drugs manufactured at the site. It now allows for greater protection of product, enhanced worker safety, and a boost in production efficiency for 30 different chemical products.

The Need for Increased Production
Janssen’s Geel chemical production plant plays a crucial role in producing Active Pharmaceutical Ingredients (APIs) for life-changing medicines to treat mental illness, allergies, women’s health issues, and gastrointestinal disorders. Significantly, the SVA process increases production to more than a dozen tons of product each year - equivalent to hundreds of millions of patient treatments annually.

Fully-Contained Process
The SVA is part of a high-containment production chain, which consists of four separate state-of-the-art production installations for weighing, production, powder handling, and material-cleaning. Consistent with the containment technology, these installations are fully enclosed, which substantially enhances quality and safety.

Project: Small Volume Area (SVA) – Powder Unit
Location: Geel, Belgium
Design-Build Partner: Janssen Pharmaceutica Chemical Production Engineering

Together, these installations constitute an isolated processing chain. Transport between the various installations is performed by means of special sealed drums which can be opened only after they are coupled to an isolator.

Every stage is executed in a fully closed way through specially designed equipment integrated in isolator technology (glove boxes). New design standards were employed due to ergonomic considerations, equipment size, and pres-
We aim for the highest quality in the development, production and marketing of drugs. We want to achieve this with the greatest possible care to the well-being of our employees, our fellow citizens and our environment.

The best possible health for as many people as possible is our objective. And our responsibilities do not stop at the company gate. We are fully aware that a company like ours is helping to shape the future of the world. That is the challenge for everyone in our company – a challenge that we gladly take upon ourselves day after day.
sure safety of placing a pneumatic transport system into the isolators.

Testing of mock-up isolators was essential to project success due to the many operations that need to be performed with the equipment such as assembly and dismantling for cleaning. A single, unworkable operation would render the entire installation unusable.

Janssen Pharmaceutica Chemical Production Engineering, the lead design firm on the project, championed the build of the detailed mock-ups, using 3-D software with walk-through mode, and involved operators, technicians, engineers and management from the start of the project, allowing for the creation of an ergonomically-designed installation that saved $300,000 with initial process flow reviews.

New design standards were employed due to ergonomic considerations, equipment size, and pressure safety of placing a pneumatic transport system into the isolators.”

Installations and Technology Platforms

Spray Dryer
During the spray drying process, a suspension is sprayed at high pressure in a drying chamber with a warm nitrogen stream. Rapid evaporation of the solvent results in a powder-particle form, making uptake in the human body easier for some products. This installation was built with patient friendliness in mind and resulted in enabling patients taking AIDS inhibitors to cut their dose from 16 pills per day down to only two pills per day.

Bromination and Hydrogenation
Two separate installations are available for these processes, and both have processes in place to meet safety standards. Geel is the only site within J&J with such a combination of installations.

Preparative Separations Techniques (PST)
In some cases, chromatography is the only way to separate two highly similar substances, and at the facility in Geel, this is accomplished on a production scale with the PST installation. This is capable of separating 2,100 kg of material in 2.5 days.

Meeting Goals for Product Quality and Safety
Overall, the facility results in a positive impact on product quality and safety.

Call for Entries
It's not too early to begin planning your submission for 2007... Don't let your company pass up this outstanding opportunity to showcase your new or renovated facility!

For complete information about the Awards program and submission procedures, contact Scott Ludlum, ISPE Director of Business Initiatives by tel: +1-813-739-2284 or by email: sludlum@ispe.org. You can also visit: www.facilityoftheyear.org
**Quality: Protection of the Product**

The SVA installation complies with EU Grade C (ISO 14644-1 Class 7 (particles > 0.5 µm) + microbial requirements), which allows for the handling of intermediate products for parenteral use. It must remain completely sanitisable through Clean-In-Place (CIP) after each campaign. Sterility is not required.

**Safety: Protection of the Operator**

For the first time, Personal Protective Equipment (PPE) is no longer necessary to protect operators from exposure to high potent APIs. The SVA itself is shielded. The installation has a Design Exposure Limit (DEL) of 50 nanogram/m³. The eight hour average ambient concentration of the product does not exceed this value.

**A Heritage of Innovation**

For more than 30 years, the Janssen Pharmaceutica site in Geel has played a crucial role within Johnson & Johnson in producing APIs for medicines – and the plant now supplies about two-thirds of worldwide chemical production for Johnson & Johnson’s pharmaceutical sector. The SVA installation is the latest example of the company’s ongoing commitment to invest in new technological innovations to ensure efficient, safe, and cost-effective delivery of high-quality medicines.

BnS Engineering and Foster Wheeler congratulate Janssen Pharmaceutica. Having worked closely with Janssen, we are proud to be associated with the innovative small volume powder unit.

---

**BnS Engineering**

bns@bns.be  www.bns.be

**Foster Wheeler**

fw_pharma@fwc.com  www.fwc.com
Wyeth Pharmaceuticals
Biotechnology Excellence in a King-Sized Package

Which comes first, the manufacturing processes or the infrastructure to house and operate the processes? In planning construction for its new biopharmaceutical campus in Grange Castle, Ireland, Wyeth Pharmaceuticals considered both from the start. The result is the largest fully-integrated facility ever built in a single phase.

One of a Kind Campus
Wyeth's new state-of-the-art BioPharma Campus at Grange Castle is not just another biotechnology facility. The campus is an innovative approach to industrial facility design. Rather than introduce another biotechnology plant, Wyeth focused on developing a homogenous campus environment where core functions drive manufacturing and material handling. Also, the dramatic use of curved stone facades and generous glass offer a building to the local community that many would be proud to live beside, in direct contrast to a normal low-key industrial complex.

The integrated campus includes three separate facilities: a Drug Development Facility to coordinate and validate the technologies and procedures required to migrate products and processes from the laboratory to the commercial production stage; a multi-product Drug Substance Facility for media preparation, fermentation, and purification stages of manufacture; and a Finished Product Facility for formulation, vial preparation, filling, capping, and inspection.

Concludes on page 28.
Providing Solutions Worldwide

Your global partner in contamination control for all your facility needs.

Reliance® and Harno® GMP Washers

Cleaning Chemistries, Steri-lants and Disinfectants

Finn-Aqua® WFI Water Stills and Pure Steam Generators

Finn-Aqua® GMP Sterilizers VHP® Bio-decontamination Systems

Comprehensive Field Service Capabilities

For more information, contact your local STERIS Sales Representative or visit our website at www.steris.com
Achieving Through Partnering

In late 1999, Wyeth had a need to quickly expand production capacity for Enbrel®, a drug used to treat rheumatoid arthritis, and Prevnar®, a vaccine that helps prevent meningitis and bacteremia in children. Motivated by patient need - and the little time patients have to wait for these life-saving drugs - Wyeth envisioned the construction of a fully-integrated biopharmaceutical facility that would allow for flexibility in processing and expandability for future products.

The big question was, “How do you design and build a new 90 acre, 1,000,000 sq. ft., facility that will house more than 1,100 employees and deliver product on schedule?”

Partnering was the answer. Wyeth fostered close relationships with government agencies, design companies, and vendors to implement an alliance contractor framework for construction activities. This allowed Wyeth to easily direct delivery speed and construction quality. The company also mobilized an Integrated Commissioning and Validation (ICV) organization, to unite all stakeholders under one organization with the sole purpose of qualifying the facility. Equally significant were the tremendously high project safety standards which resulted in Wyeth posting an overall injury rate notably lower than the national manufacturing average both in construction and operations.

Focused on project delivery, design teams conducted interactive sessions that included operators, technologists, designers, equipment suppliers, and construction organizations. Project teams targeted solutions to ensure successful operational start. For example, at an early stage in the drug substance facility design, the team decided to implement a closed process system to permit sanitization of equipment and piping without the need to re-open the system. This allowed for the protection of product quality and a lowered room classification.

For effective start-up, the operations team, engineers, construction teams, and contractors were co-located on the site. Support functions and facilities were co-located as much as possible. The ICV team was initially co-located with construction, and when the operations’ staff took up residence in the buildings, ICV was co-located with operations and site engineering staff to allow for a continuous flow of knowledge transfer and for new staff to become quickly immersed in the project. Material flow was enhanced both from area to area by use of wide enclosed corridors and in manufacturing by the use of closed loop piping and transfer systems.

A Facility for the Long Haul

With its new BioPharma Campus engineered by Jacobs Lend Lease (J LL), Wyeth has achieved much more than the distinction of owning and operating one of the world’s largest biotechnology facilities. By combining established industry best practices that optimize manufacturing with team-oriented project delivery methods that drive collaboration and overall speed to market, Wyeth has delivered a true world-class facility that will serve the company well into the coming decades.
Inspect our lineup of specialized inspection machines:

- Automated Inspection Machines for Ampoules, Vials and Syringes
- Pinhole Inspection and Leak Detection Machines for Ampoules and Vials
- Manual and Semi-Automatic Inspection Machines for Lyophilized Products
- Capsule and Tablet Appearance and Weight Inspection Machines
- Laser-based Material Analysis Machines for Tablets

To find out how you can put any of these machines to work in your plant, call 1-201-287-2111 or visit www.EisaiUSA.com
An Interview with Peter Bigelow
Facility of the Year Judging Panel Chair

Peter Bigelow, Senior Vice President, Consumer Healthcare Manufacturing for Wyeth, has served as the Judging Panel Chair of the Facility of the Year Award (FOYA) for the past two years. This year’s competition marks his last year as Chair.

In this interview, Peter gives us a behind-the-scenes look at the judging process and shares his views on how the award plays an important role in advancing the pharmaceutical manufacturing industry.

Q: Tell us about your experiences and what significant contributions the competition has made to the pharmaceutical manufacturing industry.

A: The Facility of the Year Award competition has allowed us to showcase exceptional work that’s being done by the engineering community in our industry. Typically, many of these projects would be completed without a forum for people to find out about them. This competition has enabled us – at least for some of the major and significant projects in our industry – to provide a broader forum for individuals to see and understand the innovations taking place in facility design and engineering.

Before FOYA, this type of information would be obtained through less timely and less objective methods, such as word of mouth, presentations from service providers, magazine articles, or through facility tours conducted by some of the local ISPE Chapters and Affiliates.

It’s important to note that this competition not only highlights how a certain facility was designed or built on time and under budget, it allows us to identify and showcase some of the best practices utilized in the industry today. We’ve found that some of these best practices come from some of the smaller projects and not only by “Big Pharma.”

Q: What are some of the notable technological and innovative advances you are seeing in facility design and construction and how are these advances changing the way facilities are built and pharmaceuticals are produced?

A: We are seeing a lot of modularization. That is probably the single most significant technological advance that comes through. The advantages of modularization are the flexibility and the ability to move quickly.

We’re seeing a lot of very interesting and innovative processing changes that are more efficient, have higher yields, and are more compliant in respect to Good Manufacturing Practices (GMP). The industry is becoming more highly automated, and with that increased level of efficiency, brings a higher level of compliance.

An example of innovation would be the technology employed by Biolex Therapeutics. Instead of using traditional cell culture methods, the Biolex manufacturing process employs a unique expression system. We found that to be a very intriguing new innovation in biotechnology.

In regard to the use of new technology in the entries, we did see some examples of islands of Process Analytical Technology (PAT), but none of the facilities have implemented PAT to the extent that is anticipated in the future. However, I think that in the next few years, PAT will yield a new kind of era in our industry.

Q: Why is it so important for the benefit of the industry for companies with eligible facilities to submit an entry?

A: Let me emphasize that in the past two years, each and every facility that was entered into the competition was exceptional and worthy of some kind of an award. This
Understanding the submission criteria were not ranked or weighted, which of the criteria did the judges seem to be most impressed with?

A The judges seemed to be most impressed with project uniqueness and innovation. Advances in facility design technology and excellence in execution were also important. The ability to bring the project in on time, execute it well, and follow good methodology to get it done also seemed to be important criteria.

What messages, best practices, and lessons learned can the pharmaceutical manufacturing industry take away from the competition?

A One message or lesson learned is that good project execution can be done in any part of the world. Innovative and complex technologies can be employed in any part of the world. The industry is truly global. We are producing facilities of similar quality. The way we employ technologies and techniques, and the way we carry out project execution is very similar in every part of the world. The global nature of the pharmaceutical industry is truly reflected in this competition.

Another message is that our industry is a complicated business and there is a lot of competition. Therefore, processes and facilities are getting more complicated, investments are huge at times, and the demands of the business are very significant around facility and process design.

Certainly, another message is that at the forefront of every project is the impact and improvement of quality. Everybody is talking about quality and everybody is trying to make quantum leap improvements in quality.

It’s possible that state-of-the-art facilities could be associated with large, grandiose, and expensive. Is this accurate based on your experiences reviewing submissions for the competition?

A There was a mix of large-, small- and medium-sized projects. I think the committee did a good job of not being overly enamored with a project because it was large, and tried to look at a project’s innovation, technology, and overall contributions to the industry.

State-of-the-art does not necessarily mean that it has to be big, expensive, and grandiose. And, we’re seeing state-of-the-art in every project, regardless of size.

I think “Big Pharma” is stuck in a paradigm when it comes to facility design and has trouble being creative, innovative, and flexible. In “Big Pharma,” we tend to design something the way the last project was designed and try to make incremental improvements. Some of the smaller facilities and companies – because they have a small budget and fewer resources – take a totally different approach. Sometimes that approach, which is more agile and creative, can yield excellent results.

I think that “Big Pharma” could learn from some of these smaller projects how to be more flexible and to be more focused on the real needs of the business.

What final comments do you have about the Facility of the Year Award competition and its impact on the industry?

A Personally, I think ISPE has made phenomenal contributions to the industry. ISPE brings people together from around the world – from large to small countries, from suppliers to equipment sellers – for an open, honest, and useful forum for exchanging information, for becoming educated, and for finding out about new products. ISPE has helped accelerate a lot of good engineering in our industry. These facilities are real concrete examples of what ISPE talks about all the time in its guides and courses.

It’s important for everyone in the industry to learn from each other, to understand what works and what doesn’t, and to employ innovation and good solid technologies. It’s a very good way to showcase important things that are taking place in our industry. All the competition sponsors, ISPE, Pharmaceutical Processing magazine and Interphex, have similar goals, and this competition is a real complement to what they’re trying to accomplish.

The judges we’ve been able to assemble have done a great job. They’ve been committed to this competition, had great thoughts, and used their many years of experience to collaborate and make good decisions. So, I really appreciate the committee’s efforts.

From a personal point of view, this has been a very rewarding experience for me. It’s given me an insightful glimpse of the industry. And, it’s made me feel really good about where we’re headed as an industry.
What separates the leading pharmaceutical manufacturers?

The answer is easy—they rely on DeltaV™ Batch to improve their plants’ performance.

Because unlike other pieced-together batch solutions with high time and maintenance costs, the DeltaV Batch Suite integrates engineering, operations, simulation, change management, embedded advanced control and history in a single, global database.

And it easily shares information with your enterprise planning systems through open, interoperable standards like .Net web services, XML, SQL, and OPC.

As part of the PlantWeb® digital plant architecture and its network of predictive intelligence, DeltaV Batch delivers results like faster, more modular installations, easier validation, and reduced process variability.

Put DeltaV Batch at your fingertips, for results—easy.

EasyDeltaV.com